Why is Brawn Biotech falling/rising?

As of 02-Sep, Brawn Biotech Ltd's stock price is currently at 23.25, reflecting a decrease of 0.14, or 0.6%. The stock has been underperforming recently, having fallen for the last two days with a total decline of 0.64%. Despite this short-term drop, Brawn Biotech has shown strong performance over longer periods, with a 16.89% return over the past year, significantly outperforming the broader market, which has seen negative returns. However, the company faces challenges, including weak long-term fundamentals, as indicated by an average Return on Equity (ROE) of 0% and declining net sales and operating profits over the last five years. This combination of factors contributes to a perception of risk surrounding the stock.
In the broader market context, Brawn Biotech's recent performance contrasts with the Sensex, which has declined by 0.78% over the past week. While Brawn Biotech has outperformed the benchmark in the short term with a 6.90% increase over the past week, the overall market sentiment remains negative, as evidenced by the BSE500's 4.82% decline over the last year. The stock's liquidity appears adequate, with a delivery volume increase, but the underlying financial weaknesses and a negative EBITDA position create a cautious outlook for investors.